H erpes simplex virus type 2 (HSV-2) increases susceptibility to and transmissibility of human immunodeficiency virus (HIV) by a factor of 2 to 3.
1 Herpes simplex virus type 2 can create lesions that facilitate entry of HIV and also recruits target cells to genital epithelia which increase the likelihood of acquiring HIV. Herpes simplex virus type 2 also increases the magnitude of HIV viremia in genital secretions of coinfected persons, facilitating transmission of HIV. Herpes simplex virus type 2 has been a major driver of sexual transmission of HIV in sub-Saharan Africa 2 and among non-injecting drug users (NIDUs). 3 Population-attributable risk factors analyses suggest that HSV-2 infection accounts for approximately half of HIV infections and is a major factor in racial/ethnic disparities in HIV infection among NIDUs in New York City. 3 We recently reported a significant decrease in HIV infection among NIDUs in New York City, from a prevalence of 16% in 2005 to 2010 to a prevalence of 8% in 2011 to 2014 (P < 0.001). 4 This included approximately 50% reductions in HIVamong both persons who used intranasal heroin and who smoked crack cocaine. We also noted a very low HIV incidence among the NIDUs (0.12/ 100 person-years at risk (PYAR) (95% CI 0.003/100 -0.65/100 PYAR)). In this report, we present data on the trend in HSV-2 prevalence in the same NIDU population in New York City during the same period as the decrease in HIV prevalence examine continuing associations between HIV and HSV-2 infection in this group and consider the possible implications for resurgence of HIV transmission in this high-risk group. We also consider the implications for heterosexual transmission of HIV among NIDUs in other areas of the United States.
MATERIALS AND METHODS
The data presented here were collected as part of a longrunning research study of persons entering Mount Sinai Beth Israel drug detoxification and methadone maintenance programs in New York City. The methods for this "Risk Factors" study have been previously described, 5, 6 so only a summary will be presented here. The programs serve New York City as a whole, and there were no changes in the requirements for entrance into the program over the study period.
For the analyses presented here, only persons who reported never having injected drugs are included. Hospital records and questionnaire results were checked for consistency regarding route of drug administration and subjects were examined for physical evidence of injecting.
In the detoxification program, research staff visited the general admission wards of the program in a preset order and examined all intake records of a specific ward to construct lists of patients admitted within the prior 3 days. All of the patients on the list for the specific ward were asked to participate in the study. Because there was no relationship between the assignment of patients to wards and the order that the staff rotated through the wards, these procedures should produce an unbiased sample of persons entering the detoxification program. In the methadone program, newly admitted patients (those admitted in the previous month) were asked to participate in the research. Participants were paid US $20 for their time and effort. In both programs, approximately 95% of those asked agreed to participate. Common reasons for non-participation included medical appointments or other scheduled activities that would not permit completion of study.
Written informed consent was obtained and a trained interviewer administered a computer-assisted structured questionnaire covering demographics, drug use, sexual risk behavior, and use of HIV prevention services. Most drug use and HIV risk behavior questions referred to the 6 months before the interview, before entry into the drug treatment programs. Participants were asked about multiple classes of drugs by different routes of administration.
Participants were seen by counselors for HIV pretest counseling and serum collection. The HIV testing was conducted at the NYC Department of Health Laboratory using a commercial, enzyme-linked, immunosorbent assays (EIA) test with Western blot confirmation (BioRad Genetic Systems HIV-1-2+0 EIA and HIV-1 Western Blot; BioRad Laboratories, Hercules, CA). HSV-2 testing was conducted for all subjects beginning in 2005 and was performed by BioReference Laboratories using the Focus HerpeSelect 1 and 2 ELISA (enzyme-linked immunosorbent assay). The laboratory used an index value of 1.1 or greater for classifying a subject as HSV-2 seropositive and reported results as positive/ negative for all assays. The HSV-2 reports also included index values for assays after 2006. Because there is debate about the appropriate index value for seropositivity for the Focus, 7 we also examined the HSV-2 results using an index value of 3.0 for HSV-2 assays after 2006.
A major focus of this article is to compare trends in HSV-2 among NIDUs to the recently reported decline in HIV prevalence among NIDUs 4 who were also recruited from the Mount Sinai Beth Israel drug treatment programs. We used a step-down trend test 8, 9 to identify the year when the change in HIV prevalence was significantly different from the overall fluctuations in HIV prevalence. This yielded 2 periods, 2005-2010 and 2011-2014. To maintain parallel analysis between the previous HIV trends and the HSV-2 data reported here, we used the same total study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) and also compared the same 2 periods-2005-2010 versus 2011-2014 to assess changes over time.
Subjects were permitted to participate on multiple occasions, though only once per calendar year. For trend analyses, we included persons who participated in different years in the data for each year, because these subjects were part of the population of interest (persons entering Mount Sinai Beth Israel drug treatment programs in each year).
Subjects who were HSV-2 seronegative at their first study participation and then were HSV-2 seropositive at a later participation were used as the numerator for estimating HSV-2 incidence. The denominator was the total number of years between first and last participation for subjects who remained HSV-2 seronegative plus one half of the time between the last seronegative participation and the first seropositive participation of the subjects who did seroconvert (the time at risk for the seroconverters is based on an assumption that seroconversion occurred midway between last seronegative participation and first seropositive participation). Confidence intervals for incidence values (95% CI) were calculated using the binomial test for calculating exact confidence intervals. Repeat participation subjects were matched on name, drug treatment program identification number, gender, and date of birth to ensure that these were the same individuals participating on more than one occasion. We estimated HSV-2 incidence based on both the binary yes/no, 1.1 index value, and on a 3.0 index value.
We used Cuzick test for trend, χ 2 tests and logistic regression for statistical testing. For logistic regression analyses, listwise deletion was used whenever data were missing, though there were relatively little missing data (<3% for any variable).
Stata 12 software 10 was used for statistical analyses. The study was approved by the Mount Sinai Beth Israel Institutional Review Board. Table 1 presents the demographic characteristics, recent drug use, HIVand HSV-2 prevalence of the 3157 NIDUs recruited into the study between 2005 and 2014. The subjects were predominantly male (8% of the males reported male-with-male sexual intercourse in the 5 years prior to the interview), and African-American and/or Latinx. The average age increased significantly between the two periods, and there were modest changes in the male/female and racial/ethnic group distributions. Intranasal heroin use increased and smoking crack cocaine decreased (for the 6 months prior to interview) modestly. As noted in Materials and Methods, participants were asked about multiple types of drug use. Intranasal use of heroin and smoking crack cocaine were the 2 most frequently reported types of drug use. These 2 types of drug use were not mutually exclusive. There was considerable overlap among the heroin sniffers and crack smokers: for the combined 2005 to 2014 period 33% of crack smokers also reported intranasal heroin user and 48% of intranasal heroin users also reported smoking crack. HSV-2 and HIV prevalence both decreased; HSV-2 prevalence decreased from 60.2% in 2005-2010 to 55.6% in 2011-2014, whereas HIV prevalence decreased from 15.7% in 2005-2010 to 7.6% in 2011-2014. In part due to the overlap among crack smokers and intranasal heroin users, there were parallel trends in HSV-2 prevalence among these 2 groups (see Fig. 1 ) (using an index value of 3.0 for determining HSV-2 seropositive status, HSV-2 prevalence was 55% in 2005-1010 and 51% in 2011-2014 (χ 2 = 4.2, P < 0.05.)
RESULTS

Factors Associated With Being HSV-2 Seropositive
We used multivariable logistic regression with backwards elimination to examine whether the decline in HSV-2 prevalence between 2005-2010 and 2011-2014 remained significant when controlling for demographic characteristics and recent drug use (these analyses used the 1.1 index value). Results are presented in Table 2 . The decline in HSV-2 prevalence remained statistically significant and the adjusted ORs (adjusted OR, 0.82; 95% CI, 0.70-0.97; P < 0.05) was very similar to the unadjusted odds ratio for the decline in HSV-2 prevalence (OR, 0.83; 95% CI, 0.72-0.96).
There was a significant increase of 4 years in the mean age of the NIDUs from 2005-2010 to 2011-2014 (see Table 1 ), and age was positively associated being HSV-2 seropositive (Table 2) . Tables 3A and 3B 
Sexual Risk Behavior
HIV and HSV-2 Infection
Herpes simplex virus type 2 prevalence was strongly associated with HIV seroprevalence among the NIDUs during the total period (OR, 3.9; 95% CI, 2.9-5.1) and in both 2005-2010 (OR, 3.6; 95% CI, 2.6-4.9) and 2011-2014 (OR, 4.5; 95% CI, 2.6-8.0) periods. These ORs were primarily a function of the high percentage of HIV seropositives who were also HSV-2 seropositive. In 2005-2010, 82% of HIV seropositives were also HSV-2 seropositive; in the 2011-2014, 84% of HIV seropositives were also HSV-2 seropositive.
We examined changes in the distribution of HSV-2 and HIV among the NIDUs-the percentages of subjects with (1) 
HSV-2/HIV Coinfected NIDUs on ART
A high percentage of our HSV-2/HIV coinfected NIDUs were on ART, 75% in 2005-2010 and 85% in 2011-2014 (though this increase was not statistically significant, P = 0.11). 
DISCUSSION
Because both HIV and HSV-2 viruses produce chronic infections with persistent antibodies, HIV or HSV-2 seroprevalence will decline in an at-risk population only through turnover in the population-when the sum of seropositive persons leaving the population plus the number of new seronegative persons entering the population is greater than the sum of seronegative persons leaving the population plus the seroconverters.
The data on the HSV-2 incidence rate and the decline in HSV-2 prevalence over time permit some estimation of turnover in this NIDU population. We observed an HSV-2 incidence of 1-2/100 person-years, and there was a 4.5-year time difference between the midpoint of the 2005-2010 period and the 2011-2014 period. In the absence of turnover in the population, we would have expected the HSV-2 prevalence to rise to between 64% and 68% (initial prevalence of 60% plus [1-2/100 personyears incidence Â 10 years Â 40% of HSV-2 who were initially seronegative]). Thus, turnover in the population led to a reduction of approximately 8% to 12% from the expected HSV-2 prevalence and was generating a reduction in prevalence of approximately 1% per year over the 2005-2014 period.
The relatively modest number of younger NIDUs in 2011-2014 (see Tables 3A and 3B) suggests that the primary factor in population turnover was the loss of HSV-2 seropositives rather than entry of HSV-2 seronegatives into the NIDU population. There are many reasons why HIV/HSV-2 coinfected NIDUs might leave the population of active non-injecting drug users, including disability, death, cessation of non-injecting heroin and/or cocaine use, transition to injection drug use, overdose, or factors related to aging.
The declines in HIV and HSV-2 among NIDUs occurred in the context of large-scale prevention programs in New York City. New York has implemented several evidence-based programs that would potentially reduce HIV and HSV-2 transmission among NIDUs/crack cocaine users, including the NYC condom distribution program (begun in 2007), 11 a policy of providing ART to all HIV seropositives (adapted in 2011), 12 and providing detoxification services for NIDUs/crack cocaine users. New York City also has a large methadone maintenance treatment system, which would be appropriate for many of the internasal heroin users. As a substantial percentage of the crack cocaine users also used heroin, it is possible that methadone maintenance may be helpful for some of them in reducing HSV-2/HIV risk. The condom distribution program is quite large with over 30 million free condoms distributed per year. The provision of ART to HIV seropositive NIDUs has a high coverage, as noted in the ART data above (we would also note that providing multiple interventions on a public health scale and permitting individuals to select which interventions to use is likely to produce the greatest reductions in HIV/HSV-2 transmission).
The decline in HSV-2 prevalence was modest, certainly too modest to account for the substantial reduction in HIV prevalence (from 16% to 8%, we observed in the same NIDU population over the same period). The trends in HSV-2 that we observed from 2005 to 2014, however, do suggest some population-level protection against a resurgence of HIV among the NIDUs. First, there was a decline in the potential HIV transmission from HSV-2/ HIV coinfected persons. The percentage of NIDUs with HSV-2/ HIV coinfection in the NIDU population decreased substantially, so that there would be fewer NIDUs in whom HSV-2 infection might facilitate HIV transmission. There was also a large percentage of the HSV-2/HIV coinfected NIDUs (85% during the second period) who were on ART, which would also reduce infectiousness.
Second, the percentage of NIDUs without either HSV-2 or HIV infection increased. These NIDUs would not be subject to HSV-2 facilitating acquisition of HIV.
Third, the significant reduction in the percentage of NIDUs reporting multiple sexual partners in the 6 months before the interview should also contribute to reductions in HIV and HSV-2 transmission, because having multiple sexual partners within short periods increases the likelihood of transmission for a wide variety of sexually transmitted diseases. [13] [14] [15] Continuation of these trends should reduce the chances of resurgence of HIV among NIDUs in New York City.
Although the above trends are clearly in a positive direction, the problem of HSV-2 facilitated transmission of HIV among NIDUs remains a substantial public health issue. Herpes simplex virus type 2 prevalence remains high in the NIDU population, and it is higher in socially disadvantaged groups-men who have sex with men (MSM), females, African-Americans, both in New York City (see Tables 1 and 2 ) and nationally in the United States. Herpes simplex virus type 2 among persons who use drugs has particularly been a problem in large urban areas in the United States, 16 and it may also be emerging as a problem among rural drug users. 17 Herpes simplex virus type 2 suppressive therapy has not reduced HIV transmission in large clinical trials. 18 We do not have an effective medication for the treatment of stimulant (cocaine, amphetamine type stimulants) drug disorders. Also, there is the emergence of novel psychoactive substances which may lead to increases in drug use-related unsafe sexual behavior. Thus, it is important that the large HIV prevention programs for NIDUs in New York City be maintained and strengthened if feasible.
Limitations
Several limitations of this study should be mentioned. First, all of the subjects were voluntarily entering treatment for drug problems, considerable caution should be exercised in generalizing to non-injecting drug users who use at levels that do not lead them to seek treatment for their drug use. However, previous comparisons of HIVamong persons enter Mount Sinai Beth Israel drug treatment programs with persons recruited from the community (and from other drug treatment programs) show great consistency across the various recruitment sites. 19 Second, the research design is serial cross-sectional surveys, so that we do not have direct data on the numbers of persons who left the active non-injecting drug use population. Third, our estimation of HSV-2 (and HIV) incidence comes from persons who repeatedly entered treatment for their non-injecting drug use. These NIDUs would presumably be at higher risk for drug use facilitated transmission of HIV and HSV-2, so that our observed HSV-2 incidence may be a high estimate. Fourth, we had only a modest percentage (8% of males) who reported male-with-male sexual activity and very few subjects who reported methamphetamine use, so that our results should not be generalized to MSM or to methamphetamine users in general. Fifth, we do not have data on seroconcordance/discordance or rate of partner change in the primary and casual sexual partnerships of our participants. Changes in these partnerships could serve as mechanisms for decreased transmission of HIV and HSV-2. Finally, there is no surveillance system specific to HIVor HSV-2 among non-injecting users of heroin and/or cocaine, so that we cannot match the trends in our sample with surveillance data.
We doubt that these limitations would have generated the patterns observed in the data reported here or in our previous report of declining HIV prevalence among NIDUs in New York City.
